{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T05:26:03Z","timestamp":1774761963501,"version":"3.50.1"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate whether the rate of Anti\u2010Osteoporosis Medication (AOM) dispensing was related to prevalence of risk factors and hip fracture incidence in the local population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The Open Prescribing database was used to analyse dispensed AOM at the level of Clinical Commissioning Groups (CCGs) in England. Male Healthy Life Expectancy (MHLE), Female Healthy Life Expectancy (FHLE), the prevalence of smoking and active adults, the incidence of hip fracture and of alcohol related hospital admissions, and local dispensing of a comparator drug (atorvastatin) were considered as predictor variables. Linear and multilinear regression were performed. Using atorvastatin as a comparator, AOM dispensing was compared after the start of the Covid\u201019 pandemic with the same quarter the previous year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Rates of AOM per 1000 people aged over 65\u2009years in a CCG area varied between 379.2 and 1129.1, with a mean of 670.3. Population risk factors were individually related to the amount of AOM dispensed in an area. Collectively, local activity levels in adults (p\u00a0=\u00a00.042) and local hip fracture incidence (p\u00a0=\u00a00.003) were significantly negatively correlated with rates of AOM dispensed. Rates of alendronate dispensing fell significantly at the start of the Covid\u201019 pandemic (p\u2009&lt;\u20090.001), whilst atorvastatin dispensing rates significantly increased (p\u2009&lt;\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Lower rates of AOM dispensing were seen in areas with a higher proportion of active adults and higher incidence of hip fracture. Multidisciplinary services should be developed to address this care gap with consideration given to local population risk factors. Community pharmacists are ideally placed to play a vital role in osteoporosis management.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5544","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:25:28Z","timestamp":1663673128000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti\u2010osteoporosis medication dispensing by clinical commissioning groups in England \u2013 an ecological study of variability in practice and of the effect of the Covid\u201019 pandemic"],"prefix":"10.1002","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4560-0208","authenticated-orcid":false,"given":"Sobia S.","family":"Janjua","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Policy School of Pharmacy, University of Nottingham  Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-5619","authenticated-orcid":false,"given":"Helen F.","family":"Boardman","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Policy School of Pharmacy, University of Nottingham  Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2961-8579","authenticated-orcid":false,"given":"Arvind","family":"Sami","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences Botnar Research Centre, University of Oxford  Oxford UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4726-9106","authenticated-orcid":false,"given":"Antony","family":"Johansen","sequence":"additional","affiliation":[{"name":"School of Medicine University Hospital of Wales, Cardiff University  Wales UK"},{"name":"Falls and Fragility Audit Programme Royal College of Physicians  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9228-6266","authenticated-orcid":false,"given":"Li Shean","family":"Toh","sequence":"additional","affiliation":[{"name":"Division of Pharmacy Practice and Policy School of Pharmacy, University of Nottingham  Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-0048","authenticated-orcid":false,"given":"Kassim M.","family":"Javaid","sequence":"additional","affiliation":[{"name":"Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences Botnar Research Centre, University of Oxford  Oxford UK"},{"name":"Falls and Fragility Audit Programme Royal College of Physicians  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.6.785"},{"key":"e_1_2_10_3_1","unstructured":"National Health Service. Accessed January 27 2022.https:\/\/www.nhs.uk\/conditions\/osteoporosis"},{"key":"e_1_2_10_4_1","unstructured":"International Osteoporosis Foundation. Accessed January 27 2022.https:\/\/www.iofbonehealth.org"},{"issue":"1","key":"e_1_2_10_5_1","first-page":"53","article-title":"Quality of life of the elderly after hip fracture surgery: a case\u2010control study","volume":"2","author":"Hajbaghery MA","year":"2013","journal-title":"J Caring Sci"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102474\u201012\u2010105"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy251"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3277-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S138000"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01623184"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650070902"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1998.13.12.1915"},{"key":"e_1_2_10_13_1","unstructured":"National Health Service Overview Osteoporosis. Accessed January 27 2022.https:\/\/www.nhs.uk\/conditions\/osteoporosis\/"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.11.6953"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657\u2010018\u20100439\u20103"},{"key":"e_1_2_10_16_1","unstructured":"British National Formulary (BNF) 2020BMJ Group and Pharmaceutical Press London."},{"key":"e_1_2_10_17_1","unstructured":"National Institute of Clinical Excellence (NICE) Bisphosphonates for treating osteoporosis Technology Appraisal Guidance TA464 9 August 2017. Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/ta464\/resources\/bisphosphonates-for-treating-osteoporosis-pdf-82604905556677"},{"key":"e_1_2_10_18_1","unstructured":"National Institute of Clinical Excellence (NICE) Denosumab for the prevention of osteoporotic fractures in postmenopausal women Technology Appraisal Guidance TA204 27 October 2010. Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/ta204"},{"key":"e_1_2_10_19_1","unstructured":"National Institute of Clinical Excellence (NICE) Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women Technology Appraisal Guidance TA160 Last updated: February 7 2018. Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/ta160"},{"key":"e_1_2_10_20_1","unstructured":"National Institute of Clinical Excellence (NICE) Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women Technology Appraisal Guidance TA161 Last updated: February 7 2018. Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/ta161"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1744987109357812"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010017\u20104238\u20102"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657\u2010020\u201000825\u20101"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010020\u201005542\u20106"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198\u2010020\u201005793\u20103"},{"key":"e_1_2_10_26_1","unstructured":"Open Prescribing Database.EBM DataLab University of Oxford 2020. Accessed January 27 2022.https:\/\/openprescribing.net"},{"key":"e_1_2_10_27_1","unstructured":"BBC News.The Changing NHS 01 Mar 2013. Accessed January 27 2022.https:\/\/www.bbc.co.uk\/news\/health-19674838"},{"key":"e_1_2_10_28_1","unstructured":"Office for National Statistics Table SAPE22DT6a: Mid\u20102019 Population Estimates for 2020 Clinical Commissioning Groups (CCGs) in England by Single Year of Age and Sex \u2010 National Statistics. Accessed January 27 2022.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/clinicalcommissioninggroupmidyearpopulationestimates"},{"key":"e_1_2_10_29_1","unstructured":"Office for National Statistics Population estimates for the UK England and Wales Scotland and Northern Ireland: mid\u20102019 using April 2020 local authority district codes. Accessed January 27 2022.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/datasets\/populationestimatesforukenglandandwalesscotlandandnorthernireland"},{"key":"e_1_2_10_30_1","unstructured":"National Hip Fracture database. Accessed April 30 2021.https:\/\/www.nhfd.co.uk"},{"key":"e_1_2_10_31_1","unstructured":"Office for National Statistics. What affects an area's healthy life expectancy? 28 June 2017. Accessed January 27 2022.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/healthandsocialcare\/healthandlifeexpectancies\/articles\/whataffectsanareashealthylifeexpectancy\/2018\u201001\u201018"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1385\/ENDO:23:1:01"},{"key":"e_1_2_10_33_1","volume-title":"IBM SPSS Statistics for Windows, Version 28.0","year":"2021"},{"key":"e_1_2_10_34_1","unstructured":"Office for National Statistics Table SAPE23DT6a mid\u20102020 Population estimates for Super output areas electoral wards Parliamentary constituencies Clinical Commissioning Groups and National Parks released 16 Sept 2021"},{"key":"e_1_2_10_35_1","unstructured":"National Health Service Digital Change summary \u2013 2021 CCG mergers. Accessed January 27 2022.https:\/\/digital.nhs.uk\/services\/organisation\u2010data\u2010service\/change\u2010summary\u2010reconfiguration\u20102021\u2010ccg\u2010mergers"},{"key":"e_1_2_10_36_1","unstructured":"National Institute of Clinical Excellence Osteoporosis: assessing the risk of fragility fracture. Clinical Guideline CG146. Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/cg146\/resources\/osteoporosis-assessing-the-risk-of-fragility-fracture-pdf-35109574194373"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2882"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12966\u2010020\u201001040\u20104"},{"key":"e_1_2_10_39_1","unstructured":"Ministry of Housing Communities & Local Government(2019) The English Indices of Deprivation. Accessed January 27 2022.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/835115\/IoD2019_Statistical_Release.pdf"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15096"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102012\u2010002337"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-003-1499-8"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afy141.43"},{"key":"e_1_2_10_44_1","unstructured":"National Institute of Clinical Excellence(2020). Accessed January 27 2022.https:\/\/www.nice.org.uk\/guidance\/ng167\/resources\/covid19-rapid-guideline-rheumatological-autoimmune-inflammatory-and-metabolic-bone-disorders-pdf-66141905788357"},{"key":"e_1_2_10_45_1","unstructured":"Pharmaceutical Services Negotiating Committee(2021) About community pharmacy. Accessed January 27 2022.https:\/\/psnc.org.uk\/psncs-work\/about-community-pharmacy\/"},{"key":"e_1_2_10_46_1","unstructured":"HsiehJEcological fallacy.Encyclopedia Britannica 4 September 2017. Accessed January 27 2022.https:\/\/www.britannica.com\/science\/ecological-fallacy"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5544","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5544","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5544","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:02:48Z","timestamp":1692576168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1002\/pds.5544"],"URL":"https:\/\/doi.org\/10.1002\/pds.5544","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"2022-04-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}